Patents Assigned to Shanghai Benemae Pharmaceutical Corporation
  • COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    Publication number: 20230201311
    Abstract: Disclosed herein are compositions comprising GLP-1 and/or GLP-1 analog(s) for treating or preventing non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: July 18, 2022
    Publication date: June 29, 2023
    Applicant: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
    Inventors: Zhiqiang DU, Xiankang FANG, Qingqin LAI, Yan QIU, Peng WU
  • COMBINATIONAL THERAPY COMPRISING GLP-1 AND/OR GLP-1 ANALOGS, AND INSULIN AND/OR INSULIN ANALOGS
    Publication number: 20230092769
    Abstract: Disclosed herein are combinational therapies for diabetes comprising a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs and a second effective amount of one or more second active ingredients selected from the group consisting of insulin and insulin analogs.
    Type: Application
    Filed: July 18, 2022
    Publication date: March 23, 2023
    Applicant: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
    Inventors: Yajun ZUO, Xiankang FANG, Zhiqiang DU, Jing XIA
  • DOSING REGIMEN OF GLP-1
    Publication number: 20230081034
    Abstract: Disclosed herein are dosing regimens of GLP-1 and/or GLP-1 analog(s).
    Type: Application
    Filed: July 18, 2022
    Publication date: March 16, 2023
    Applicant: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
    Inventors: Huiqing SANG, Hai LU, Zhiqiang DU, Xiankang FANG
  • GLP-1 COMPOSITION FOR TREATING OBESITY AND WEIGHT MANAGEMENT
    Publication number: 20210052703
    Abstract: Disclosed herein is a pharmaceutical composition containing a recombinant human GLP-1 peptide and use thereof. The human GLP-1 peptide and the pharmaceutical composition can be used for preventing or treating obesity, bulimia, and/or overweight. Other related uses include weight management (e.g. inducing weight loss), slowing stomach emptying, increasing satiety, etc.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 25, 2021
    Applicant: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
    Inventors: Zhiwen YU, Yajun ZUO, Jing XIA, Shichuang WANG, Lifen QIAN
  • PEG modified exendin or exendin analog and compositions and use thereof
    Patent number: 9175060
    Abstract: Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified exendin or exendin analog, methods of making or administering the modified exendin or exendin analog, and various uses thereof are also provided.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: November 3, 2015
    Assignee: Shanghai Benemae Pharmaceutical Corporation
    Inventors: Wenchao Bao, Hongjing Xu, Gang Yu, Yajun Zuo